Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH — Clinical Trial Site

54 Registered trials

24 Currently recruiting

Organisation

Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH

Location

Berlin, Germany

Identifier

ORG-100044105

Address

Lindenberger Weg 27, Buch, 13125, Germany

Departments

-
#173: Klinik für Pneumologie
#2005:Klinik fuer Pneumologie
2604:Klinik für Pneumologie
Clinic for Pneumology
Department of Pneumology
DEU005: Klinik für Pneumologie
Evangelische Lungenklinik
Evangelische Lungenklinik Berlin
Klinik fuer Pneumologie
Klinik für Pneumologie
Lunge
N/A
Oncology
Pneumologie
Pneumology
Pneumology and Cardiology
Studienabteilung
Studienzentrum

Clinical trials at this site (54)

Search interface

A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu… Pending

2024-517561-16-00 non-small cell lung cancer 4
Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros… Pending

2024-518013-25-00 Idiopathic Pulmonary Fibrosis 4
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 EGFR-mutated Non-small Cell Lung Cancer 10
Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting

2025-522107-18-00 Locally advanced or metastatic Non-Small Cell Lung Canc 4 2026-05-19
A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can… Recruiting

2025-522437-65-00 small-cell lung cancer 4 2026-03-06
A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca… Recruiting

2024-519901-36-00 Patients with resected stage II-IIIA non-small cell lun 5 2025-12-17
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting

2024-516790-78-00 stage IV NSCLC (non-small-cell lung cancer) 4 2025-09-04
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Non small cell lung cancer (NSCLC) 5 2024-01-24
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Large cell neuroendocrine carcinoma 4 2023-10-17
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab… Recruiting

2024-517490-24-00 Small Cell Lung Cancer 4 2026-03-31
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Neuroendocrine tumors 10 2026-01-27
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting

2024-513613-12-00 Part A: Healthy volunteers (Part A is not applicable to 9 2025-09-18
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 non-small cell lung cancer 5 2025-08-27
Safety and clinical parameter assessment of self-infusion therapy with Prolastin® in patients with severe AATD Recruiting

2024-515894-80-00 Severe Alpha-1 Antitrypsin Deficiency (AATD) 5 2025-07-01
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting

2023-509883-89-00 Epidermal growth factor receptor (EGFR) mutation-positi 5 2025-01-09